SCHEMBL20116273

SCHEMBL20116273

CC(C)n1ncc2ccc(-c3nc(C4CN(C(=O)CC(C)(C)C)C4)no3)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.41
SCD5 Q86SK9 1/20 0.39
PTGER3 P43115 1/20 0.36
HTR4 Q13639 1/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NR1H4 Q96RI1 2/20 0.34
S1PR4 O95977 1/20 0.34
S1PR1 P21453 1/20 0.34
S1PR5 Q9H228 1/20 0.34
HSD11B1 P28845 1/20 0.34
CPT1A P50416 1/20 0.34
USP7 Q93009 1/20 0.33
ALOX5AP P20292 1/20 0.33
FLT3 P36888 1/20 0.33
IKBKE Q14164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116368 0.93 USP30 (0.42) USP30SCD5PTGER3HTR4ALDH1A1
SCHEMBL22358288 0.91 USP7 (0.40) USP30PTGER3HTR4NR1H4USP7
SCHEMBL20116268 0.86 USP30 (0.46) USP30SCD5PTGER3ALDH1A1KDM4E
SCHEMBL22358124 0.84 GRM5 (0.44)
SCHEMBL20116353 0.81 USP30 (0.54) USP30TBK1
SCHEMBL20676474 0.80 USP30 (0.41) USP30SCD5PTGER3HTR4ALDH1A1
SCHEMBL20117082 0.80 TBK1 (0.44) USP30PTGER3HTR4ALDH1A1NR1H4
SCHEMBL22357992 0.79 SMN1; SMN2 (0.44) ALDH1A1NPC1RAB9A
SCHEMBL22358472 0.79 USP30 (0.48) USP30ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL20116656 0.78 S1PR1 (0.36) SCD5PTGER3NPC1S1PR4S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 USP30 3526/4885SCD5 1575/4885PTGER3 1760/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 USP30 3526/4885SCD5 1575/4885PTGER3 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.